Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity

Area of Science:

• Biomedical Engineering
• Materials Science
• Oncology

Background:

• Cisplatin (CDDP) is a potent anticancer drug but causes significant nephrotoxicity.
• Developing drug delivery systems can improve cisplatin's therapeutic index.

Purpose of the Study:

• To synthesize and evaluate cisplatin-incorporated polymeric micelles (CDDP/m) for enhanced antitumor activity and reduced toxicity.
• To compare the in vitro and in vivo performance of CDDP/m with free CDDP.

Main Methods:

• Ligand substitution reaction to bind CDDP to poly(ethylene glycol)-poly(aspartic acid) (PEG-P(ASP)) block copolymer.
• Formation of CDDP-loaded micelles (CDDP/m) with improved water solubility.
• In vitro cytotoxicity assays against human tumor cell lines.
• In vivo studies in rodents evaluating pharmacokinetics, tumor drug levels, antitumor activity (MKN 45 xenograft), and renal toxicity.

Main Results:

• CDDP/m exhibited 10-17% of CDDP's in vitro cytotoxicity.
• Intravenous administration of CDDP/m resulted in higher and more sustained serum levels compared to CDDP.
• In vivo, CDDP/m showed higher and sustained drug levels in tumor tissue.
• CDDP/m demonstrated comparable antitumor activity to CDDP against gastric cancer xenografts.
• CDDP/m treatment significantly reduced cisplatin-induced nephrotoxicity.

Conclusions:

• CDDP/m represents a promising formulation for reducing cisplatin-induced nephrotoxicity.
• The polymeric micelle system maintains the anticancer efficacy of cisplatin.
• CDDP/m offers a potential strategy for safer and more effective cisplatin-based cancer chemotherapy.